These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 9033723)
1. [Light and heavy chain deposition disease with cutaneous and renal manifestations]. Safa G; Dhib M; Soubrane JC; Thomine E; Delpech A; François A; Joly P; Lauret P Ann Dermatol Venereol; 1996; 123(8):490-2. PubMed ID: 9033723 [TBL] [Abstract][Full Text] [Related]
2. [Non-amyloidotic glomerular disease caused by light-chain deposits: a case report]. Cantillo Jde J; López Rdel P; Andrade RE Biomedica; 2009 Dec; 29(4):531-8. PubMed ID: 20440451 [TBL] [Abstract][Full Text] [Related]
3. Proliferative glomerulonephritis with discrete deposition of monoclonal immunoglobulin γ1 CH 2 heavy chain and κ light chain: a new variant of monoclonal immunoglobulin deposition disease. Komatsuda A; Ohtani H; Sawada K; Joh K; Wakui H Pathol Int; 2013 Jan; 63(1):63-7. PubMed ID: 23356227 [TBL] [Abstract][Full Text] [Related]
4. [Light chain deposition disease]. Terzani E; Alterini B; Doni M; Lampronti V; Lusini C; Fazzini G Ann Ital Med Int; 1994; 9(2):100-4. PubMed ID: 7917761 [TBL] [Abstract][Full Text] [Related]
5. Nonamyloidotic monoclonal immunoglobulin deposits lack amyloid P component. Gallo G; Picken M; Frangione B; Buxbaum J Mod Pathol; 1988 Nov; 1(6):453-6. PubMed ID: 3146753 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal free light chains can be found in heavy chain diseases. López-Anglada L; Puig N; Díez-Campelo M; Alonso-Ralero L; Barrena S; Aparicio MA; Gutiérrez NC; García-Sanz R Ann Clin Biochem; 2010 Nov; 47(Pt 6):570-2. PubMed ID: 20930031 [TBL] [Abstract][Full Text] [Related]
13. [Heavy chain deposition disease: report of a case and review of the literature]. Imai H Rinsho Byori; 2001 Jul; 49(7):695-8. PubMed ID: 11519134 [TBL] [Abstract][Full Text] [Related]
14. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F; Javaugue V; Bender S; Leroy F; Aucouturier P; Debiais-Delpech C; Goujon JM; Quellard N; Bonaud A; Clavel M; Trouillas P; Di Meo F; Gombert JM; Fermand JP; Jaccard A; Cogné M; Touchard G; Sirac C Kidney Int; 2017 Feb; 91(2):423-434. PubMed ID: 27773425 [TBL] [Abstract][Full Text] [Related]
16. Light chain deposition disease without detectable light chains in serum or urine. Report of a case and review of the literature. van Ingen G; van Bronswijk H; Meijer CJ; Stel HV Neth J Med; 1991 Oct; 39(3-4):142-7. PubMed ID: 1791875 [TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Ronco P; Plaisier E; Mougenot B; Aucouturier P Clin J Am Soc Nephrol; 2006 Nov; 1(6):1342-50. PubMed ID: 17699367 [TBL] [Abstract][Full Text] [Related]
19. A concurrence of light and heavy chain deposition disease and diabetic nephropathy. Satirapoj B; Paueksakon P J Med Assoc Thai; 2007 Oct; 90(10):2204-8. PubMed ID: 18041443 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal immunoglobulin G1-kappa fibrillary glomerulonephritis. Grove P; Neale PH; Peck M; Schiller B; Haas M Mod Pathol; 1998 Jan; 11(1):103-9. PubMed ID: 9556416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]